Reata Pharmaceuticals
Irving
About Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases. It offers antioxidant and inflammation-modulating drugs, as well as drugs that correct protein misfolding. The company also develops drugs for the treatment of renal, cardiovascular, and autoimmune diseases. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: Less than $1M
- Total funding: $2.0B
- Funding stage: M&A
- Last round: Post-IPO Debt (May 2023)
- Ticker: nasdaq:RETA
- Website: reatapharma.com
- Phone: 972-865-2219
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/reata-pharmaceuticals-96876 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.